Risk of inpatient epistaxis admission related to oral anticoagulation medication use
© 2023 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society..
We utilized a case control study to determine if novel oral anticoagulants were associated with a higher risk of inpatient epistaxis admission. Adult patients admitted with a principal diagnosis of epistaxis in 2019-2021 were identified as well as a control group of patients matched 1:1 for age, sex, race, and medical comorbidities. For both cohorts, the presence or absence of an oral anticoagulant, classified as vitamin K inhibitors, direct oral anticoagulants (DOAC) or platelet inhibitors, was identified. 158 adult unique inpatient admissions with a principal diagnosis of epistaxis were identified. Vitamin K inhibition was present in 5.7% of cases versus 0.6% of controls (p = 0.02; OR 9.48, range 1.19-75.77), DOACs in 4.4% of cases versus 5.1% of controls (p = 1.0) and platelet inhibitors in 2.5% of cases versus 3.8% of controls (p = 0.75). We concluded vitamin K inhibitors, compared to DOACs and platelet inhibitors, may be associated with higher likelihood of epistaxis admission.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Laryngoscope investigative otolaryngology - 8(2023), 4 vom: 20. Aug., Seite 824-826 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mitchell, Margaret B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Admission |
|---|
| Anmerkungen: |
Date Revised 26.08.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/lio2.1111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361195311 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361195311 | ||
| 003 | DE-627 | ||
| 005 | 20231226084623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/lio2.1111 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM361195311 | ||
| 035 | |a (NLM)37621276 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mitchell, Margaret B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of inpatient epistaxis admission related to oral anticoagulation medication use |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.08.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society. | ||
| 520 | |a We utilized a case control study to determine if novel oral anticoagulants were associated with a higher risk of inpatient epistaxis admission. Adult patients admitted with a principal diagnosis of epistaxis in 2019-2021 were identified as well as a control group of patients matched 1:1 for age, sex, race, and medical comorbidities. For both cohorts, the presence or absence of an oral anticoagulant, classified as vitamin K inhibitors, direct oral anticoagulants (DOAC) or platelet inhibitors, was identified. 158 adult unique inpatient admissions with a principal diagnosis of epistaxis were identified. Vitamin K inhibition was present in 5.7% of cases versus 0.6% of controls (p = 0.02; OR 9.48, range 1.19-75.77), DOACs in 4.4% of cases versus 5.1% of controls (p = 1.0) and platelet inhibitors in 2.5% of cases versus 3.8% of controls (p = 0.75). We concluded vitamin K inhibitors, compared to DOACs and platelet inhibitors, may be associated with higher likelihood of epistaxis admission | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DOAC | |
| 650 | 4 | |a admission | |
| 650 | 4 | |a anticoagulation | |
| 650 | 4 | |a aspirin | |
| 650 | 4 | |a clopidogrel | |
| 650 | 4 | |a epistaxis | |
| 650 | 4 | |a warfarin | |
| 700 | 1 | |a Workman, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharyya, Neil |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Laryngoscope investigative otolaryngology |d 2016 |g 8(2023), 4 vom: 20. Aug., Seite 824-826 |w (DE-627)NLM265973406 |x 2378-8038 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:4 |g day:20 |g month:08 |g pages:824-826 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/lio2.1111 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 4 |b 20 |c 08 |h 824-826 | ||